1.
|
Please provide us, with a view toward disclosure in the prospectus, with the total dollar value of the securities underlying the convertible notes that you have registered for resale (using the number of underlying securities that you have registered for resale and the market price per share for those securities on the date of the sale of the convertible notes).
|
2.
|
Please provide us, with a view toward disclosure in the prospectus, with tabular disclosure of the dollar amount of each payment (including the value of any payments to be made in common stock) in connection with the transaction that you have made or may be required to make to the selling shareholders, any affiliate of the selling shareholders, or any person with whom the selling shareholders have a contractual relationship regarding the transaction (including any interest payments, liquidated damages, payments made to "finders" or "placement agents," and any other payments or potential payments). Please provide footnote disclosure of the terms of each such payment. Please do not include any repayment of principal on the convertible notes in this disclosure.
|
Party
|
Payments in Cash
|
Other Payments
|
Sanders Ortoli Vaughn-Flam LLP
|
$150,000
|
750,000 warrants
|
Greenberg Traurig LLP
|
$100,000
|
None
|
Olympus Securities LLC
|
$64,000
|
1,400,000 warrants
|
|
●
|
as disclosed in Section 15 of its Form D filed on June 2, 2010, the Company paid Olympus Securities LLC a finder’s fee of $64,000 and 1,400,000 warrants (500,000 Series A Warrants, 400,000 Series B Warrants and 500,000 Series C Warrants). This payment was in exchange for finding investors who accounted for $800,000 of the $1,275,000 in gross proceeds to the Company from the sale. The Company has no further obligations to make payments to Olympus Securities LLC.
|
|
●
|
as set out in Section 4(g) of the Securities Purchase Agreement governing the Transaction, the Company is required to pay $100,000 to Greenberg Traurig LLP to cover the legal fees and expenses of Iroquois Master Fund Ltd., $90,000 of which was paid at the time of the Transaction and $10,000 of which is still to be paid.
|
3.
|
Please provide us, with a view toward disclosure in the prospectus, with tabular disclosure of:
|
|
•
|
the total possible profit the selling shareholders could realize as a result of the conversion discount for the securities underlying the convertible notes, presented in a table with the following information disclosed separately:
|
|
•
|
the market price per share of the securities underlying the convertible notes on the date of the sale of the convertible notes;
|
|
•
|
the conversion price per share of the underlying securities on the date of the sale of the convertible notes, calculated as follows:
|
|
-
|
if the conversion price per share is set at a fixed price, use the price per share established in the convertible note; and
|
|
-
|
if the conversion price per share is not set at a fixed price and, instead, is set at a floating rate in relationship to the market price of the underlying security, use the conversion discount rate and the market rate per share on the date of the sale of the convertible note and determine the conversion price per share as of that date;
|
•
|
the total possible shares underlying the convertible notes (assuming no interest payments and complete conversion throughout the term of the note);
|
•
|
the combined market price of the total number of shares underlying the convertible notes, calculated by using the market price per share on the date of the sale of the convertible notes and the total possible shares underlying the convertible notes;
|
•
|
the total possible shares the selling shareholders may receive and the combined conversion price of the total number of shares underlying the convertible notes calculated by using the conversion price on the date of the sale of the convertible notes and the total possible number of shares the selling shareholders may receive; and
|
•
|
the total possible discount to the market price as of the date of the sale of the convertible notes, calculated by subtracting the total conversion price on the date of the sale of the convertible notes from the combined market price of the total number of shares underlying the convertible notes on that date.
|
Market Price
|
||||||
<$0.30
|
$0.35
|
$0.40
|
$0.45
|
$0.50
|
$0.55
|
|
% Profit
|
<0%
|
16.6%
|
33.3%
|
50%
|
66.5%
|
83.3%
|
Market Price
|
||||||
$0.10
|
$0.15
|
$0.20
|
$0.25
|
$0.30
|
$0.35
|
|
% Profit
|
17.6%
|
17.6%
|
17.6%
|
17.6%
|
17.6%
|
17.6%
|
4.
|
Please provide us, with a view toward disclosure in the prospectus, with tabular disclosure of:
|
|
•
|
the total possible profit to be realized as a result of any conversion discounts for securities underlying any other warrants, options, notes, or other securities of the issuer that are held by the selling shareholders or any affiliates of the selling shareholders, presented in a table with the following information disclosed separately:
|
|
•
|
market price per share of the underlying securities on the date of the sale of that other security;
|
|
•
|
the conversion/exercise price per share as of the date of the sale of that other security, calculated as follows:
|
|
-
|
if the conversion/exercise price per share is set at a fixed price, use the price per share on the date of the sale of that other security; and
|
|
-
|
if the conversion/exercise price per share is not set at a fixed price and, instead, is set at a floating rate in relationship to the market price of the underlying security, use the conversion/exercise discount rate and the market rate per share on the date of the sale of that other security and determine the conversion price per share as of that date;
|
•
|
the total possible shares to be received under the particular securities (assuming complete conversion/exercise);
|
•
|
the combined market price of the total number of underlying shares, calculated by using the market price per share on the date of the sale of that other security and the total possible shares to be received;
|
•
|
the total possible shares to be received and the combined conversion price of the total number of shares underlying that other security calculated by using the conversion price on the date of the sale of that other security and the total possible number of underlying shares; and
|
•
|
the total possible discount to the market price as of the date of the sale of that other security, calculated by subtracting the total conversion/exercise price on the date of the sale of that other security from the combined market price of the total number of underlying shares on that date.
|
|
(i)
|
the Notes described in the Amended Registration Statement and for which we have described the potential profits on conversion in our response to your comment 3 above and
|
(ii)
|
the Warrants, the conversion discount of which relates to a full-ratchet adjustment (for both the reduction of the exercise price of such Warrants and an increase in the amount of such Warrants) upon the issuance of securities at a price per share less than the exercise price then in effect. We do not anticipate any such dilutive issuances.
|
5.
|
Please provide us, with a view toward disclosure in the prospectus, with tabular disclosure of:
|
•
|
the gross proceeds paid or payable to the issuer in the convertible notes transaction;
|
•
|
all payments that have been made or that may be required to be made by the issuer that are disclosed in response to Comment 2;
|
•
|
the resulting net proceeds to the issuer; and
|
•
|
the combined total possible profit to be realized as a result of any conversion discounts regarding the securities underlying the convertible notes and any other warrants, options, notes, or other securities of the issuer that are held by the selling shareholder or any affiliates of the selling shareholder that is disclosed in response to Comments 3 and 4.
|
Gross Proceeds
|
$ | 1,275,000 | ||
Required Payments (made or to be made)
|
$ | 314,000 | ||
Resulting Proceeds to Issuer
|
$ | 961,000 | ||
Total possible profit resulting from conversion discount upon Company conversion (excluding original issue discount) with a market price of $0.353 or less (above $0.353, there is no conversion discount).
|
$ | 269,892 |
6.
|
Please provide us, with a view toward disclosure in the prospectus, with tabular disclosure of all prior securities transactions between the issuer (or any of its predecessors) and the selling shareholders, any affiliates of the selling shareholders, or any person with whom the selling shareholders have a contractual relationship regarding the transaction (or any predecessors of those persons), with the table including the following information disclosed separately for each transaction:
|
•
|
the number of shares of the class of securities subject to the transaction that were outstanding prior to the transaction;
|
•
|
the number of shares of the class of securities subject to the transaction that were outstanding prior to the transaction and held by persons other than the selling shareholders, affiliates of the company, or affiliates of the selling shareholders;
|
•
|
the number of shares of the class of securities subject to the transaction that were issued or issuable in connection with the transaction;
|
|
•
|
the percentage of total issued and outstanding securities that were issued or issuable in the transaction (assuming full issuance), with the percentage calculated by taking the number of shares issued and outstanding prior to the applicable transaction and held by persons other than the selling shareholders, affiliates of the company, or affiliates of the selling shareholders, and dividing that number by the number of shares issued or issuable in connection with the applicable transaction;
|
|
•
|
the market price per share of the class of securities subject to the transaction immediately prior to the transaction (reverse split adjusted, if necessary); and
|
|
•
|
the current market price per share of the class of securities subject to the transaction (reverse split adjusted, if necessary).
|
Name
|
Date of Transaction
|
Approximate Outstanding Shares at time of Transaction
|
Approximate Public Float less Holder’s Shares at Time of Transaction
|
Number of Shares Issuable in Transaction
|
Approximate % of Total Outstanding Shares Issued to Holder at time of Transaction
|
Market Price Per Share at Time of Transaction
|
Nagelberg
|
8/30/09
|
36,414,666
|
19,075,529
|
875,000 (1)
|
2.4%
|
$1.26
|
(1)
|
Represents a $350,000 debenture convertible into 437,500 common shares and warrants convertible into 437,500 common shares at $1.20 per share. These securities were exchanged for a Note and Warrants in the Transaction.
|
7.
|
Please provide us, with a view toward disclosure in the prospectus, with tabular disclosure comparing:
|
|
•
|
the number of shares outstanding prior to the convertible notes transaction that are held by persons other than the selling shareholders, affiliates of the company, and affiliates of the selling shareholders;
|
|
•
|
the number of shares registered for resale by the selling shareholders or affiliates of the selling shareholders in prior registration statements;
|
•
|
the number of shares registered for resale by the selling shareholders or affiliates of the selling shareholders that continue to be held by the selling shareholders or affiliates of the selling shareholders;
|
•
|
the number of shares that have been sold in registered resale transactions by the selling shareholders or affiliates of the selling shareholders; and
|
|
•
|
the number of shares registered for resale on behalf of the selling shareholders or affiliates of the selling shareholders in the current transaction.
|
Number of shares
|
|
Shares outstanding prior to the Transaction
|
40,256,027
|
Shares outstanding prior to the Transaction that are held by the selling shareholders, affiliates of the Company, and affiliates of the selling shareholders
|
17,132,595
|
Shares outstanding prior to the Transaction that were held by persons other than the selling shareholders, affiliates of the Company, and affiliates of the selling shareholders
|
23,123,342
|
Shares registered for resale by the selling shareholders or affiliates of the selling shareholders in prior registration statements
|
0
|
Shares registered for resale by the selling shareholders or affiliates of the selling shareholders in prior registration statements that continue to be held by the selling shareholders or affiliates of the selling shareholders
|
0
|
Shares that have been sold in registered resale transactions by the selling shareholders or affiliates of the selling shareholders
|
0
|
Shares registered for resale on behalf of the selling shareholders or affiliates of the selling shareholders in the current transaction
|
30,523, 500
|
8.
|
Please provide us, with a view toward disclosure in the prospectus, with the following information:
|
|
•
|
whether the issuer has the intention, and a reasonable basis to believe that it will have the financial ability, to make all payments on the overlying securities; and
|
|
•
|
whether - based on information obtained from the selling shareholders - the selling shareholders have an existing short position in the company's common stock and, if the selling shareholders have an existing short position in the company's stock, the following additional information:
|
|
-
|
the date on which the selling shareholders entered into that short position; and
|
|
-
|
the relationship of the date on which the selling shareholders entered into that short position to the date of the announcement of the convertible note transaction and the filing of the registration statement (e.g., before or after the announcement of the convertible note transaction, before the filing or after the filing of the registration statement, etc.).
|
·
|
fail to pay any amounts due on the notes,
|
·
|
fail to have this registration declared effective by the SEC by September 30, 2010 or maintain its effectiveness once declared,
|
·
|
spend more in any month or in any area as set out in the notes and the Securities Purchase Agreement related to the notes,
|
·
|
maintain indebtedness in excess of $250,000 and
|
·
|
issue equity securities in the next six months, other than those expressly permitted by the notes.
|
|
9.
|
Please provide us, with a view toward disclosure in the prospectus, with:
|
|
•
|
a materially complete description of the relationships and arrangements that have existed in the past three years or are to be performed in the future between the issuer (or any of its predecessors) and the selling shareholders, any affiliates of the selling shareholders, or any person with whom the selling shareholders have a contractual relationship regarding the transaction (or any predecessors of those persons) - the information provided should include, in reasonable detail, a complete description of the rights and obligations of the parties in connection with the sale of the convertible notes; and
|
|
•
|
copies of all agreements between the issuer (or any of its predecessors) and the selling shareholders, any affiliates of the selling shareholders, or any person with whom the selling shareholders have a contractual relationship regarding the transaction (or any predecessors of those persons) in connection with the sale of the convertible notes.
|
10.
|
Please provide us, with a view toward disclosure in the prospectus, with a description of the method by which the company determined the number of shares it seeks to register in connection with this registration statement. In this regard, please ensure that the number of shares registered in the fee table is consistent with the shares listed in the "Selling Security Holders" section of the prospectus.
|
11.
|
With respect to the shares to be offered for resale by the selling security holders,
|
|
please disclose the natural person or persons who exercise sole or shared voting
|
|
and/or dispositive powers with respect to the shares to be offered by each shareholder.
|
“Name of Selling
Stockholder and Position, Office or Material Relationship with TapImmune
|
Number of Shares of Common Stock Owned Prior to Offering
|
Maximum Number of
Shares of Common
Stock to be Sold
Pursuant to this
Prospectus (2)
|
Total Shares Registered (3)
|
Number of Shares of Common Stock Owned by Selling Stockholder After Offering and Percent of Total Issued and Outstanding(1)
|
|
# of Shares
|
% of Class
|
||||
Iroquois Master Fund Ltd. (4)
|
0
|
9,576,0007,200,000
|
9,576,000
|
0
|
0
|
Next View Capital L.P. (5)
|
0
|
9,576,0007,200,000
|
9,576,000
|
0
|
0
|
CGM Custodian for the IRA of David S. Nagelberg (6)
|
0
|
8,379,0006,300,000
|
8,379,000
|
0
|
0
|
Prufrock Partners Ltd. (7)
|
0
|
2,992,5002,250,000
|
2,992,500
|
0
|
0
|
(1)
|
Based on 70,779,527 shares of common stock, which includes 40,256,027 shares of common stock issued and outstanding on July [--]June 15, 2010 and all 30,523,500 shares of common stock being offered in this prospectus that may be issued upon conversion of the notes and exercise of the warrants. In determining this amount, we assumed that all 30,523,500 shares included in this prospectus will be sold. If this assumption is incorrect, the number of shares and percentages included in this column will differ from what we have provided.
|
(2)
|
Includes shares of Common Stock underlying warrants and/or notes held by the Selling Stockholder that are covered by this prospectus, including any convertible securities that, due to contractual restrictions, may not be exercisable if such exercise would result in beneficial ownership greater than 4.9% and 9.9%, as applicable.
|
(3)
|
In accordance with the terms of a registration rights agreement with the holders of the notes and the warrants, the number of shares of Common Stock to be sold by each Selling Stockholder under this prospectus generally covers the resale of 133% of the number of shares of Common Stock issuable upon conversion of the notes at the conversion price and the number of shares of Common Stock issuable upon exercise of the warrants. See “Description of Securities To Be Registered – Warrants and Convertible Notes.”
|
(4)
|
Iroquois Capital Management L.L.C. (“Iroquois Capital”) is the investment manager of Iroquois Master Fund Ltd. (“Iroquois Master Fund”) and consequently has voting control and investment discretion over securities held by Iroquois Master Fund. Each of Joshua Silverman and Richard Abbe may be deemed to have voting control and investment discretion over securities held by Iroquois Master Fund. As a result of the foregoing, each of Iroquois Capital, Mr. Silverman and Mr. Abbe may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities being registered hereunder.
|
(5)
|
Stewart Flink has sole voting and investment control over the shares held by Next View Capital LP.
|
(6)
|
David A. Nagelberg has sole voting and investment control over the shares held by CGM Custodian for the IRA of David S. Nagelberg.
|
(7)
|
Prufrock Management Ltd. (“PML”) is the investment manager of Prufrock Partners Ltd. (“Prufrock”) and consequently has voting control and investment discretion over securities held by Prufrock. Steven A. Sanders is the sole shareholder of PML and, as a result, has voting control and investment discretion over securities held by Prufrock.”
|
Sincerely,
|
|
TapImmune Inc.
|
|
/s/ Denis Corin
|
|